文献速递神经免疫

继发进展型多发性硬化:新见解

Secondary Progressive Multiple Sclerosis: New Insights.
PubMed 文献 · Neurology · 2021-06-04

本文综述继发进展型多发性硬化(SPMS)的病理、鉴别诊断及诊疗挑战,强调从复发缓解型(RRMS)向SPMS转化的关键性。目前尚无明确的临床、影像、免疫或病理标准界定这一转化,早期识别SPMS需借助工具并结合适当治疗以改善长期结局。

要点

  • SPMS由RRMS转化而来,残疾进展独立于临床复发。
  • RRMS与SPMS对治疗的反应存在重大差异。
  • 尚无明确标准界定RRMS向SPMS的转化,需早期识别工具。

核心结论

  • 从RRMS向SPMS的转化至关重要,既是残疾进展的证据,也因既往有效治疗在SPMS中未证有效。

研究设计与样本

  • 综述,总结SPMS的病理、鉴别诊断及诊疗挑战。

主要发现

  • RRMS与SPMS在治疗反应等方面存在重大差异。
  • 尚未建立明确标记RRMS向SPMS转化的临床、影像、免疫或病理标准。

临床怎么用

  • 早期识别SPMS需借助工具,并结合适当治疗以改善长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In most cases, multiple sclerosis (MS) begins with a relapsing-remitting course followed by insidious disability worsening that is independent from clinically apparent relapses and is termed secondary progressive MS (SMPS). Major differences exist between relapsing-remitting MS (RRMS) and SPMS, especially regarding therapeutic response to treatment. This review provides an overview of the pathology, differentiation, and challenges in the diagnosis and treatment of SPMS. We emphasize the criticality of conversion from a relapsing-remitting to a secondary progressive disease course not only because such conversion is evidence of disability progression, but also because, until recently, treatments that effectively reduced disability progression in relapsing MS were not proven to be effective in SPMS. Clear clinical, imaging, immunologic, or pathologic criteria marking the transition from RRMS to SPMS have not yet been established. Early identification of SPMS will require tools that, together with the use of appropriate treatments, may result in better long-term outcomes for the population of patients with SPMS.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Cree BAC, Arnold DL, Chataway J, et al. Secondary Progressive Multiple Sclerosis: New Insights. Neurology. 2021. PMID: 34088878. doi:10.1212/WNL.0000000000012323

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。